A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in Subjects With Parkinson's Disease With a Pathogenic Variant in the Glucocerebrosidase (GBA1) Gene
Details
Age
Adult
Type of Study
Treatment
Locations
Brain Imaging Center (BIC)
Outpatient CTRC
University of Colorado Hospital
Principal Investigator
Emily Forbes, DO
Study ID
Protocol Number: 23-0328
More information available at ClinicalTrials.gov: NCT05819359
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers